TrialLeukemia & lymphoma2013

Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.

Danielle Brander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.